SiRIC CURAMUS

What SiRIC CURAMUS does

SiRIC CURAMUS is a French publicly-funded integrated cancer research consortium (Site de Recherche Intégrée sur le Cancer) labeled by the Institut National du Cancer (INCa) as one of eight nationally designated sites. Established in 2018 and institutionally embedded within the AP-HP.Sorbonne Université hospital-university group, the consortium integrates Sorbonne Université's three faculties (Medicine, Sciences-Engineering, Letters) in association with Inserm and CNRS. It coordinates translational and clinical research on three priority disease programs: neuro-oncology (brain tumors), rare immuno-hematological cancers, and cancers with microsatellite instability (MSI). Three transversal programs—AI & Data Management, Medical Humanities, and Life After Cancer—sit alongside the disease programs to broaden the research remit.

The consortium's operating infrastructure includes four national research networks (CANCERVIH, CONECT-AML, K-VIROGREF, RENOCLIP-LOC), the CLIP² Galilée early-phase clinical trials platform hosting approximately 80 active trials across five hospitals, and dedicated registries including COVHEMATO (COVID-19 in hematology patients) and DOREMy (AML). Technology development activity includes the SonoCloud implantable ultrasound device for glioblastoma treatment (€2.9M AP-HP funding), CAR-T cell therapy production in partnership with Novartis Cell For Cure, and high-throughput genomic analysis using Foundation Medicine data across approximately 10,000 tumors. Patient flow is approximately 16,000 cases annually (including 10,000 new cases) across seven AP-HP hospitals.

SiRIC CURAMUS does not generate commercial revenue. Operating funds are sourced from French public institutional channels—INCa (label, CLIP², ParPedia19, emergence calls), DGOS, Inserm, ITMO Cancer AVIESAN, and the Ministry of Health—plus university/hospital support and tax-deductible donations routed through the AP-HP Research Foundation. The organization serves cancer patients (including HIV-positive and transplant-immunocompromised cohorts), clinician-researchers across the AP-HP and Sorbonne ecosystem, and patient associations. Research outputs are disseminated via peer-reviewed publications, scientific conferences, and educational programs including the European Master's in Cancer Control and Université des Patients, with no commercial products or services sold.

Name

SiRIC CURAMUS

Legal name

SiRIC CURAMUS - Direction de la recherche et de l'innovation, Groupe hospitalier universitaire AP-HP.SORBONNE UNIVERSITÉ

Website

https://curamus-cancer.fr

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

SiRIC CURAMUS is a French publicly-funded integrated cancer research consortium operating under INCa labeling as one of eight national SiRIC sites, coordinating translational and clinical research across AP-HP.Sorbonne Université hospitals on brain tumors, rare immuno-hematological cancers, and MSI cancers.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Cancer research consortium
• Translational oncology research
• Clinical trials coordination
• Genomic cancer analysis
• Medical humanities research

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Others

Revenue model

1. Public Institutional Funding: Core funding from French government cancer research agencies including INCa (Institut National du Cancer), DGOS (Direction Générale de l'Offre de Soins), and Inserm. Labeled as SiRIC (Site de Recherche Intégrée sur le Cancer) receiving designated financial support.
2. University and Hospital Support: Financial and operational support from AP-HP.Sorbonne Université through the Direction de la recherche et de l'innovation, and ITMO Cancer AVIESAN.
3. Donations and philanthropy: Accepts donations from public with tax reduction benefits (66% for income tax, 75% for IFI), with funds managed through AP-HP Research Foundation.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

SiRIC CURAMUS is an integrated academic cancer research consortium conducting translational and clinical research across three specialized programs: Neuro-oncology, Rare Immuno-hematological Cancers, and Microsatellite Instability (MSI) Cancers. It delivers research outputs, coordinates early-phase clinical trials (CLIP² Galilée), operates the AI & Data Management Hub for bioinformatics and machine learning training, and runs medical humanities and patient education programs. The consortium also develops medical technologies such as the implantable SonoCloud ultrasound device for glioblastoma treatment in collaboration with industry partners.

Product overview

SiRIC CURAMUS (Site de Recherche Intégrée sur le Cancer) is an integrated cancer research site labeled by INCa, operating as a research platform with three main research programs (Neuro-oncology, Rare Immuno-hematological Cancers, and MSI Cancers), two transversal programs (AI & Data Management Hub and Medical Humanities), and one societal program (Life After Cancer). The organization also operates educational programs including the European Master's Degree in Cancer Control (4EU+ Alliance), University Degree in Immunocompromised Cancer, and the Patients University. Key research infrastructure includes CANCERVIH, CONECT-AML, K-VIROGREF, and RENOCLIP-LOC networks, the CLIP² Galilée early phase clinical trials center, COVHEMATO COVID-19 registry, DOREMy pediatric leukemia database, and SonoCloud medical device for glioblastoma treatment. The AI & Data Management Hub provides machine learning and bioinformatics services through partnership with Sorbonne Center for Artificial Intelligence.

Differentiator

Problem solved

Functional benefit

Products and services

• Neuro-oncology Research Program (Programme 1) Research program focused on brain, cancer, and immunity with cellular dialogue in brain tumors, investigating genetic mechanisms involved in resistance to brain tumor treatments including hypermutation in gliomas and oligodendroglioma formation. Targets academic medical researchers and clinician-researchers.
• Rare Immuno-hematological Cancers Research Program (Programme 2) Research program studying rare and aggressive hematological cancers including pediatric leukemia and cancers in immunosuppressed patients (HIV, transplant recipients). Explores genomic characterization, CAR-T cell therapy, and innovative treatments. For academic researchers and rare cancer patient populations.
• Microsatellite Instability (MSI) Cancer Research Program (Programme 3) Research program dedicated to MSI cancers of all locations including colon, stomach, endometrium, pancreas, prostate, lung, breast, ovary, and brain. Focuses on immunotherapy and immune checkpoint inhibitors. Targets researchers and clinicians working on MSI tumors.
• AI & Data Management Hub (Hub IA & DM) Transversal AI and data management program offering Discovering AI training (Python, machine learning basics, data visualization) and specialized bioinformatics analysis services. Supports predictive oncology research for SiRIC CURAMUS members and affiliated researchers.
• Medical Humanities Transversal Program Transversal program bringing together philosophers, sociologists, and information/communication researchers to provide critical reflections on health democracy, patient experts, rare cancers, cure, and personalized medicine. Targets academic researchers integrating social sciences into oncology.
• Life After Cancer Societal Program Societal program addressing life after illness, right to oblivion for access to loans, and return to employment. Coordinated by patient representatives from associations and the University of Patients. Targets cancer survivors and patient associations.
• European Master's Degree in Cancer Control (4EU+ Alliance) Multidisciplinary training programme in cancerology developed with Alliance 4EU+ partner universities. Open to students from Sorbonne University, Charles University Prague, Heidelberg, Warsaw, Milan, and Copenhagen. Targets graduate students in oncology and cancer control.
• University Degree in Immunocompromised Cancer Diploma program for optimizing management of immunocompromised cancer patients (HIV or transplant patients). Covers oncology in immunosuppressed persons, oncogenic viruses, and new anti-tumor therapies. Targets medical professionals and clinician-researchers.
• Université des Patients (Patients University) Innovative pedagogical device integrating patient-experts from the associative world into university degree programs in therapeutic education. Hosts three Diplomas: health democracy, patient journey accompaniment, and therapeutic education. Targets patient experts and patient representatives.
• CANCERVIH Network National network coordinating cancer research and care for immunocompromised patients (HIV-positive, transplant recipients), including immunotherapy efficacy studies. Targets HIV-positive cancer patients and clinicians across France.
• CONECT-AML Network Network of 12 research teams in France focused on pediatric acute myeloid leukemia. Includes genomic analyses and new experimental models. Targets pediatric oncology researchers and clinicians.
• K-VIROGREF Network Network dedicated to viral infections in transplant recipients and cancer patients. Coordinates research across multiple French centers. Targets virology researchers and transplant clinicians.
• RENOCLIP-LOC Network Research network focused on rare solid tumors and their clinical research coordination across multiple French sites. Targets researchers and clinicians working on rare solid tumor oncology.
• Immunotherapy for HIV-positive Cancer Patients Clinical Research Service

Quantifiable outcome

• 33% objective response rate in MSI/dMMR metastatic colorectal cancer patients treated with pembrolizumab (KEYNOTE-164 study)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

Partnerships

14 partnerships are on record, tiered major and core.

• 4EU+ AlliancemajorStrategic or Co-development Partner · 1 February 2019European university alliance of six institutions (Sorbonne Université, Charles Prague, Heidelberg, Warsaw, Milan, Copenhagen) with 286,940 students and €368M budget, developing joint cancer research and the European Master's Degree in Cancer Control.
• CONECT-AML NetworkmajorStrategic or Co-development Partner · 1 January 2017Pediatric oncology research network of 12 teams in France created under PAIR program, focused on acute myeloid leukemia since 1989.
• InsermcoreStrategic or Co-development PartnerFrench National Institute of Health and Medical Research providing institutional partnership and co-funding for cancer research programs alongside INCa and Ministry of Health.
• Sorbonne UniversitécoreStrategic or Co-development PartnerPrincipal academic partner bringing together Faculty of Medicine, Sciences-Engineering, and Letters under the Institut Universitaire de Cancérologie (IUC) federation.
• AP-HP (Assistance Publique - Hôpitaux de Paris)coreStrategic or Co-development PartnerUniversity hospital group providing research infrastructure and patient populations across seven hospital sites (Pitié Salpêtrière, Saint Antoine, Tenon, Trousseau, Rothschild, Charles Foix, La Roche Guyon).
• CNRScoreStrategic or Co-development PartnerFrench National Centre for Scientific Research collaborating on fundamental and translational cancer research alongside Inserm and university partners.
• CLIP² GaliléecoreStrategic or Co-development PartnerINCa-labeled early phase clinical trials center coordinated at Pitié-Salpêtrière, operating 80 trials across five hospitals, supported by SiRIC CURAMUS.
• CANCERVIH NetworkcoreStrategic or Co-development PartnerFrench national network dedicated to cancer in immunocompromised patients (HIV-positive, transplant recipients), coordinated by Prof. Jean-Philippe Spano.
• K-VIROGREF NetworkmajorStrategic or Co-development PartnerResearch network addressing viral infections in immunocompromised transplant recipients and cancer patients.
• RENOCLIP-LOC NetworkmajorStrategic or Co-development PartnerNetwork focused on rare solid tumors and their clinical research coordination.
• Novartis Cell For CuremajorStrategic or Co-development PartnerCAR-T cell therapy production center collaborating on immunotherapy manufacturing for hematological cancer treatments.
• Dana-Farber Cancer Institute (Harvard Medical School)majorStrategic or Co-development PartnerInternational collaboration with neuro-oncology teams on glioma hypermutation research, combining global sample of 10,000 tumors.
• Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP)majorStrategic or Co-development PartnerResearch institute where virology teams (TheraVir) conduct therapeutic strategy research for HIV and associated viral diseases.
• Sorbonne Center for Artificial Intelligence (SCAI)majorTechnology or IntegrationPartnership for Developing AI training program providing machine learning education to SiRIC CURAMUS researchers.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Institut Bergonié: CLCC in Bordeaux, France, focused on adult oncology research and treatment. Comparable as a French CLCC with academic partnerships (Université de Bordeaux) running early phase trials and translational research in solid tumors.
• Gustave Roussy: France's leading comprehensive cancer center and the largest in Europe, located in Villejuif near Paris. Directly comparable as a major French cancer research and treatment institution conducting translational oncology research, early phase clinical trials, and biomarker-driven precision medicine programs.
• Institut Curie: Leading French cancer research center combining a hospital with a research center in Paris. Comparable in scope as a multidisciplinary oncology institution focused on translational research, immunotherapy, and rare cancers, with similar Paris-based academic-medical integration.
• Centre Léon Bérard: CLCC (Comprehensive Cancer Center) in Lyon focused on oncology research, treatment, and education. Comparable as a French cancer center running early phase clinical trials and translational research programs with similar academic hospital partnerships.
• Institut de Cancérologie de l'Ouest (ICO): CLCC operating two sites in western France (Nantes, Angers). Comparable as a French comprehensive cancer center running clinical trials and translational oncology research programs with hospital-academic integration.
• Dana-Farber Cancer Institute: Harvard Medical School-affiliated cancer research and treatment center in Boston. Already an active international research partner of SiRIC CURAMUS for glioma hypermutation research — directly comparable in combining large-scale genomic research, immunotherapy development, and translational/clinical programs.
• Institut Paoli-Calmettes: CLCC located in Marseille, one of France's 18 comprehensive cancer centers. Comparable as a regional French cancer center with similar translational research, immunotherapy focus, and academic partnerships (Inserm, CNRS, Aix-Marseille Université).

Others

• EORTC: European Organisation for Research and Treatment of Cancer — a pan-European clinical cancer research infrastructure. Comparable as a coordinating body for multi-institutional translational oncology research and clinical trials across European academic cancer centers.
• UNICANCER: Federation of the 18 French CLCCs (including Gustave Roussy, Institut Curie, Centre Léon Bérard, and Institut Paoli-Calmettes). Comparable as the organizational umbrella representing the same type of French cancer research institutions that SiRIC CURAMUS engages with through its hospital network.

Broad incumbents

• MD Anderson Cancer Center: The largest comprehensive cancer center in the United States, affiliated with the University of Texas. Comparable as a global leader in translational oncology research, early phase clinical trials, immunotherapy, and precision oncology — operating at much larger scale but with a similar academic-medical integrated model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/curamus
• Facebookfacebook.com/cancercuramus
• LinkedInlinkedin.com/company/siric-curamus

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SiRIC CURAMUS